1. Home
  2. CINGW vs LANC Comparison

CINGW vs LANC Comparison

Compare CINGW & LANC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • LANC
  • Stock Information
  • Founded
  • CINGW N/A
  • LANC 1961
  • Country
  • CINGW United States
  • LANC United States
  • Employees
  • CINGW 13
  • LANC N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • LANC Packaged Foods
  • Sector
  • CINGW Health Care
  • LANC Consumer Staples
  • Exchange
  • CINGW Nasdaq
  • LANC Nasdaq
  • Market Cap
  • CINGW N/A
  • LANC N/A
  • IPO Year
  • CINGW 2021
  • LANC N/A
  • Fundamental
  • Price
  • CINGW $0.03
  • LANC $190.33
  • Analyst Decision
  • CINGW
  • LANC Buy
  • Analyst Count
  • CINGW 0
  • LANC 4
  • Target Price
  • CINGW N/A
  • LANC $211.33
  • AVG Volume (30 Days)
  • CINGW N/A
  • LANC 170.7K
  • Earning Date
  • CINGW N/A
  • LANC 04-30-2025
  • Dividend Yield
  • CINGW N/A
  • LANC 1.99%
  • EPS Growth
  • CINGW N/A
  • LANC 21.25
  • EPS
  • CINGW N/A
  • LANC 5.69
  • Revenue
  • CINGW N/A
  • LANC $1,900,130,000.00
  • Revenue This Year
  • CINGW N/A
  • LANC $5.03
  • Revenue Next Year
  • CINGW N/A
  • LANC $3.31
  • P/E Ratio
  • CINGW N/A
  • LANC $33.60
  • Revenue Growth
  • CINGW N/A
  • LANC 1.77
  • 52 Week Low
  • CINGW N/A
  • LANC $163.20
  • 52 Week High
  • CINGW N/A
  • LANC $202.63
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • LANC 61.99
  • Support Level
  • CINGW N/A
  • LANC $181.55
  • Resistance Level
  • CINGW N/A
  • LANC $193.40
  • Average True Range (ATR)
  • CINGW 0.00
  • LANC 5.80
  • MACD
  • CINGW 0.00
  • LANC 1.51
  • Stochastic Oscillator
  • CINGW 0.00
  • LANC 86.29

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: